Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Watchful waiting for prostate cancer: a review article

Prostate Cancer and Prostatic Diseases volume 9, pages 25–29 (2006)Cite this article

Abstract

As earlier detection of prostate cancer increases because of prostate-specific antigen (PSA) testing, appropriate use for watchful waiting warrants re-evaluation. We have drawn together the significant watchful waiting literature and used it to evaluate the use of watchful waiting in the PSA era. We conducted literature searches for studies examining outcomes of watchful waiting and examined new literature emerging about the use of PSA for the follow-up of watchful waiting patients. Watchful waiting has the potential to play an increasingly important role in prostate cancer as less advanced disease is detected and methods are refined for identifying low-risk patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ et al. High grade prostatic intraepithelial (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994; 8: 439–443.

    PubMed  CAS  Google Scholar 

  2. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J . Long term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626–631.

    Article  CAS  PubMed  Google Scholar 

  3. Albertsen PC, Hanley JA, Gleason DF, Barry MJ . Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 1008–1010.

    Article  Google Scholar 

  4. Albertsen PC, Hanley JA, Fine J . 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095–2101.

    Article  CAS  PubMed  Google Scholar 

  5. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Krusemo UB, Kraal W . Natural history of localized prostatic cancer. A population-based study in 223 untreated patients. Lancet 1989; 8642: 799–803.

    Article  Google Scholar 

  6. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB . High 10 year survival rate in patients with early, untreated prostatic cancer. JAMA 1992; 267: 2191–2196.

    Article  CAS  PubMed  Google Scholar 

  7. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO . Fifteen year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997; 277: 467–471.

    Article  CAS  PubMed  Google Scholar 

  8. Johansson JE, Andren O, Andersson SO, Dickman P, Holmberg L, Magnusson A et al. Natural history of early, localized prostate cancer. JAMA 2004; 291: 2713–2719.

    Article  CAS  PubMed  Google Scholar 

  9. Chodak GW, Thisted RA, Gerber GS, Johansson J, Adolfsson J, Jones GW et al. Results of conservative management of clinically localized prostate cancer. N Eng J Med 1994; 330: 242–248.

    Article  CAS  Google Scholar 

  10. Gerber GS, Thisted RA, Scardino PT, Frohmuller HG, Schroeder FH, Paulson DF et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996; 276: 615–619.

    Article  CAS  PubMed  Google Scholar 

  11. Holmberg L, Bill-Axelson A, Helgessen F, Sako JO, Folmerz P, Haggman M et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781–789.

    Article  PubMed  Google Scholar 

  12. Bill Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977–1984.

    Article  CAS  PubMed  Google Scholar 

  13. Wilt TJ, Brawer MK . The Prostate Cancer Intervention Versus Observation Trial (PIVOT). Oncology 1997; 11: 1133–1139.

    PubMed  CAS  Google Scholar 

  14. Epstein JI, Walsh PC, Brendler CB . Radical prostatectomy for impalpable prostate cancer: the John Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol 1994; 152: 1721–1729.

    Article  CAS  PubMed  Google Scholar 

  15. Klotz LH . Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 2004; 172: 48–60.

    Article  Google Scholar 

  16. Klotz LH . Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 2005; 47: 16–21.

    Article  PubMed  Google Scholar 

  17. Klotz LH . Active surveillance with selective delayed intervention: walking the line between over treatment for indolent disease and under treatment for aggressive disease. Can J Urol 2005; 12 (Suppl): 53–57.

    PubMed  Google Scholar 

  18. Epstein JI, Sanderson H, Carter HB, Scharfstein DO . Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 2005; 66: 356–360.

    Article  PubMed  Google Scholar 

  19. Carter CA, Donahue T, Sun L, Wu H, Mcleod DG, Amling C et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 2003; 21: 4001–4008.

    Article  PubMed  Google Scholar 

  20. Meng MV, Elkin EP, Harlan SR, Mehta SS, Lubeck DP, Carrol PR et al. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. J Urol 2003; 170: 2279–2283.

    Article  PubMed  Google Scholar 

  21. Wu H, Sun L, Moul JW, Wu HY, Mcleod DG, Amling C et al. Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. J Urol 2004; 171: 111–116.

    Google Scholar 

  22. el-Geneidy M, Garzotto M, Panagiotou I, Hsieh YC, Mori M, Peters L et al. Delayed therapy with curative intent in a contemporary prostate cancer watchful waiting cohort. BJU Int 2004; 93: 501–505.

    Article  Google Scholar 

Download references

Acknowledgements

Katherine Warren supported by Midwest Urology Research Foundation.

Author information

Authors and Affiliations

  1. Midwest Urology Research Foundation, Chicago, IL, USA

    G W Chodak & K S Warren

Authors
  1. G W Chodak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K S Warren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K S Warren.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chodak, G., Warren, K. Watchful waiting for prostate cancer: a review article. Prostate Cancer Prostatic Dis 9, 25–29 (2006). https://doi.org/10.1038/sj.pcan.4500857

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500857

Keywords

This article is cited by

Search

Advanced search

Quick links